NAD takes issue with University Medical
This article was originally published in The Tan Sheet
The National Advertising Division recommends University Medical Pharmaceuticals discontinue claims that compare the effects of its WrinkleFree Eyes to those of Botox, the Council of Better Business Bureaus division says Aug. 19. NAD says the firm should discontinue claims such as, "Clinically proven to reduce wrinkle appearance up to 85 percent in only 20 minutes" and "Truly effective topical alternative to Botox" because of a lack of evidence. NAD asks that the firm remove before-and-after photographs because the lighting, posing and cosmetic application are different in the first photo. The firm said the photos are not misleading. The Irvine, Calif., firm said it is disappointed with NAD's decision, but will consider the recommendations and modify its advertising accordingly
You may also be interested in...
University Medical Pharmaceuticals continues to have trouble supporting its competitive marketing claims to the satisfaction of the National Advertising Division
Device Week, 05 March - Remote Monitoring Reimbursement, T-cell Diagnostics And A Digital Health Feature
In this week's podcast, managing editor Marion Webb discusses a new monthly digital health roundup which will soon feature on Medtech Insight. Managing editor Reed Miller discusses reimbursement difficulties as it applies to remote cardiac monitoring. UK-based reporter Barnaby Pickering gives an overview of an interview with the chief medical officer of Adaptive Biotechnologies about its new T-Detect platform.
Coronavirus Notebook: Italy Makes First Use Of EU’s Vaccine Export Control System, More Regulators Issue Guidance On Variants
Ukraine has established a system for issuing emergency use authorizations for COVID-19 vaccines that recognizes authorizations granted by other world regulators.